Abstract
An open clinical trial is described in which twenty-six patients suffering from rheumatoid arthritis and related conditions (ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus) were treated with mefenamic acid. The drug was administered in a dose of 1500 mg daily for an average of twenty-five days. In 55% of the cases treated the clinical response was very good or good. There was a distinct improvement in spontaneous pain, morning stiffness, pressure tolerance, swelling, mobility and muscle power. No significant improvement was observed in ESR or other biological parameters. Drug tolerance was very good and in no case was it necessary to discontinue treatment. Mefenamic acid appeared to be effective in the management of rheumatoid arthritis and related inflammatory conditions.
Get full access to this article
View all access options for this article.